In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MorphoSys: Accelerating The Long Transformation

Executive Summary

Flush with funds from new partnering deals and recent capital injections, German biotech MorphoSys plans to boost its already considerable R&D spending to build value in the pipeline while holding on to promising assets longer.

You may also be interested in...



MorphoSys Hopes FDA Incentive Programs Can Boost Proprietary Plans

MorphoSys’s ambition to grow a proprietary pipeline got a boost with FDA giving its lead compound MOR208 fast track status for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Evotec Drug Development Strategy Offers Little Downside, Big Upside

Germany’s Evotec hopes to evolve into an integrated multi-service biopharma company through its three-pronged business strategy comprising a high-growth drug-discovery business, a series of pipeline options that pose no financial obligation for the biotech, and a growing list of scientific collaborations that offer potential long-term value.

Deal Watch: Hep C M&A Still Thriving; Plus AstraZeneca/Synairgen, MorphoSys/Merck Serono, ViiV/J&J

Merck beats out bids from AbbVie and Johnson & Johnson for Idenix Pharmaceuticals, gaining possession of three promising HCV drug candidates.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV004125

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel